NeuroOne Medical Tech Q1 2024 GAAP EPS $(0.14), Inline, Sales $977.65K Beat $852.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
NeuroOne Medical Technologies Corporation (NMTC) reported Q1 2024 GAAP EPS of $(0.14), meeting analyst consensus. Quarterly sales reached $977.65K, surpassing the $852K estimate, marking a 753.25% increase from the previous year.
February 13, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroOne Medical Technologies Corporation (NMTC) reported a Q1 2024 EPS of $(0.14), in line with estimates, and sales of $977.65K, exceeding expectations and showing significant year-over-year growth.
The reported earnings per share (EPS) of $(0.14) met analyst expectations, indicating stability in financial performance. The significant beat on sales estimates and the remarkable year-over-year sales growth of 753.25% are likely to be viewed positively by investors, potentially leading to a short-term positive impact on NMTC's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100